NEWS: Prothena Discontinues Development of NEOD001 for AL Amyloidosis


On April 23rd, 2018, Prothena Corporation plc announced the discontinuation of the development of NEOD001, an investigational monoclonal antibody targeting circulating soluble and deposited amyloid found in patients with AL Amyloidosis. The decision was made based on results from the Phase 2b PRONTO study and a fuity analysis of the Phase 3 VITAL study, according to Prothena. You can read more about the decision below:

View all posts